Posted by Michael Wonder on 11 Sep 2017
Institute for Clinical and Economic Review posts draft scoping document to guide review of emicizumab for haemophilia A
11 September 2017 - Document open to public comment until 29 September 2017.
The ICER has posted a draft scoping document outlining its planned review of the comparative clinical effectiveness and value of emicizumab for prevention of bleeding in patients with haemophilia A who have inhibitors to coagulation factor VIII. The scoping document will be open to public comment for three weeks until Friday, 29 September 2017 at 5 pm ET.
It will inform development of a report that will be subject to public deliberation during a March 2018 meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC), one of ICER’s three independent evidence appraisal committees.
